

Minutes of the **Somerset Prescribing Forum** held in **Meeting Room 1, Wynford House, Lufton Way, Yeovil, Somerset** on **Wednesday 19th July 2017**

Present:	Mark Ashley (MA)	Deputy Chief Pharmacist, Taunton & Somerset NHS FT
	Dr Clare Barlow (CB)	Chair, Drug & Therapeutics Committee, Taunton & Somerset NHS FT
	Steve Du Bois (SDB)	Chief Pharmacist- Head of Medicines Management, Somerset Partnership NHS Foundation Trust
	Shaun Green (SG)	Associate Director, Head of Medicines Management, NHS Somerset CCG
	Catherine Henley (CH)	Medicines Manager, NHS Somerset CCG
	Gordon Jackson (GJ)	Patient Representative
Apologies:	Jon Standing (JS)	Chief Pharmacist, Yeovil District Hospital
	Jon Beard (JB)	Chief Pharmacist, Taunton & Somerset NHS FT
	Dr Geoff Sharp (GS)	GP Delegate (Central Mendip Commissioning Locality), Chair
	Kate Jones (KJ)	Symphony lead pharmacist
	Dr Orla Dunn (OD)	Consultant in Public Health, Somerset County Council
	Ann Lee (AL)	Clinical Director, St Margaret's Hospice
	Michael Lennox (ML)	Chief Officer, Somerset LPC
	Dr Robert Munro (RM)	GP, Somerset Local Medical Committee representative
Jean Perry (JP)	Commissioning Manager, NHS Somerset CCG	
Zoe Talbot-White (ZT)	Prescribing Support Technician, NHS Somerset CCG	

1 INTRODUCTIONS

SG welcomed everyone to the meeting.

2 APOLOGIES

Apologies were provided as detailed above.

3 DECLARATIONS of INTEREST

No new declarations of interest.

4 MINUTES OF THE MEETING HELD ON 17th May 2017

4.1

The Minutes of the meeting were agreed as an accurate record.

4.2 SG ran through the action points from the last meeting. Most actions were either complete or, raised on the agenda.

The following action points were specifically noted:

- Hyperhidrosis pathway- SG is asking trusts to look at the policy today and move towards medical management including ProBanthine.
- Medical App approval- SG explained that medical apps now have to be licensed as medical devices. However, not all apps relate to prescribing and therefore SPF should not review those apps that are not prescribing related.
- MPH has provided some staff education around appropriately requesting 'Just in Case' boxes .
- NICE guidance on familial breast cancer- Trusts have asked breast cancer services whether they are using anastrozole in this group of patients
- YDH pre-operative anaemia guidance- a couple of comments have been fed back to YDH.

5 MATTERS ARISING

5.1 Pharmacy Transformation Plan- YDH & TST

JS reported that at YDH :

- patient facing services and digital transformation roadmap are well laid out.
- pharmacy stock system will go live at the end of Sept.
- Electronic Prescribing and Medicines Administration (EPMA) will have a phased launch from around April and electronic discharge summaries will follow.
- JS is collecting some data around PbR excluded activity.
- there is some collaborative outsourcing work.
- The Trust is working with NHS England around 7 day services.

MA reported that at TST :

- a new technician has been recruited to lead the implementation of the new pharmacy system.
- EMPA will commence from April.
- a strategy for implementation of 7 day services has just been finalised.
- they are in discussions to provide home care via a commercial partner.

SG commented that the STP needs to recognise the differences between Trusts.

5.2 LMWH Bridging Guidance- YDH Update

JS reported that Paul Latimer is the YDH DVT/ PE lead and he will pick up discussions around the guidance.

Add to the SPF agenda for September

Action: CH

5.3 Traffic light status of SSRIs in under 18 year olds guidance

SG explained that the decision on whether to prescribe in this group of patients will fall to individual GP clinical freedom.

Amber Traffic Light Status (TLS) agreed and agreed form of words will be added to the formulary regarding guidance in this group.

Action: CH

5.4 **Review of SPF Terms of Reference**

Agreed and approved subject to the following minor amendments:

- include statement on monitoring spend vs budget for high cost drugs.
- 4.9 Amend typo to read 'ensure'
- 4.10 include Patient Access Schemes

5.5 **Antipsychotics in learning difficulties – SomPar Data**

LH reported that the audit team are finalising the report and that Dr Lucy Knight has been reviewing opportunities for deprescribing on Magnolia ward.

Bring report to Sept meeting, if ready.

Action LH

6 **OTHER ISSUES**

6.1 **Interface between primary and Secondary Care: Key messages for NHS clinicians and managers**

SG commented that the document sets out key national requirements and touches on shared care. It was noted that pragmatic arrangements are needed.

JP has raised a few issues with hospitals not issuing 'fit notes.'

6.2 **IBS Pathway**

- Approved virtually by the YDH DTC.
- Cascade it to GPs via the bulletin.
- There are also webinars on this pathway created by the NHS England 100 Day Project.

Members should feedback formal comments to JS

Action: All

6.3 **Lithium Shared Care Protocol**

Agreed and approved- subject to the following amendments:

- Calcium monitoring should be every 6 months and should appear on separate line.
- b.p. should be amended to read 'blood pressure'

Action: CH

6.4 **Proposal to change traffic light status of ALAI & PP3M with inclusion in shared care arrangement**

This was discussed earlier at PAMM. It was agreed that 3 monthly paliperidone injections would be **Amber**. TLS to be updated.

Action Steve

Moore

However, the funding of GPs to administer aripiprazole under the enhanced service for injectable antipsychotics needs to be looked at before amending the TLS of this drug. Dr Rob Munro is looking into this for LMC.

Shared care guideline needs to be updated.

Action: CH

- 7 Formulary Applications**
- 7.1** Mezzopram® (Omeprazole) Dispersible Gastro-resistant Tablets; 28 x 10mg £6.58, 28 x 20mg £9.86, 28 x 40mg £4.93 (Sandoz)
- Cost effective brand **-Approved**
Add to formulary ; **Green TLS** **Action: Steve Moore**
- 7.2** Ralvo® (700mg Lidocaine Medicated Plaster); £61.54 x30 plasters (Grunenthal)
- Cost effective brand **-Approved**
Add to formulary ; **Green TLS** **Action: Steve Moore**
- 7.3** Neomag® (Magnesium glycerophosphate 4mmol) chewable tablets; £22.77 x50 tablets (Neoceuticals Ltd)
- Licensed for Hypomagnesaemia **-Approved**
Add to formulary ; **Green TLS** **Action: Steve Moore**
- 7.4** TransiSoft® (Macrogol 3350) powder for oral solution in sachet; 28 sachets £3.89 (HFA Healthcare)
- Plain Flavour, Cost effective brand **-Approved**
Add to formulary ; **Green TLS** **Action: Steve Moore**
- 7.5** Eysano® (Timolol mealeate) eye drops; 2.5mg/ml x5ml £8.45, 5mg/ml x5ml £9.65 (Aspire)
- Preservative free.Licensed for ocular hypertension, chronic open-angle glaucoma **-Approved**
Add to formulary; **Green TLS** **Action: Steve Moore**
- 7.6** Epistatus® 10mg oromucosal solution; 1x 1ml £60.00 (Special Products Ltd)
- Licensed for the treatment of prolonged, acute, convulsive seizures in children and adolescents aged 10 to less than 18 years. Cost effective for patients that rarely require oral administration.
 - Discuss with secondary to care to establish whether they will be using this brand for patients.
- Action: SG**
- A switch is only recommended when caregivers have been trained to administer.
-Approved
Add to formulary; **Green TLS** **Action: Steve Moore**
- 7.7** Relevtec® (Buprenorphine) patches
- 35mcg/h x4 £11.06, 52.5mcg/h x4 £16.60, 70mcg/h x4 £22.12 (Sandoz)
Relevtec should be replaced after 96 hours. Cost effective brand **-Approved**
Add to formulary; **Green TLS** **Action: Steve Moore**

- 7.8** Mysimba 8mg/90mg prolonged release tablets– Naltrexone/Bupropion (Consilient Health); 112 tablets £73.
- Indicated, as an adjunct to a reduced-calorie diet and increased physical activity, for the management of weight in obese adults and overweight adults with related co-morbidity.
- Not Recommended; Black TLS** - update TLS **Action: Steve Moore**
- Reconsider if specialists bring an application.
- 7.9** Truberzi 75mg & 100mg film-coated tablets – Eluxadoline (Allergan); 56 tablets £88.20
- Indicated in adults for the treatment of irritable bowel syndrome with diarrhoea.
 - A recent review from MTRAC shows that the evidence for eluxadolide for this indication was considered relatively weak.
- Not Recommended; Black TLS** - update TLS **Action: Steve Moore**
- Reconsider if specialists bring an application.
- 7.10** Xaggitin XL prolonged release tablets- Methylphenidate (Ethypharma); 30x18mg £15.58; 30x27mg £18.40; 30x36mg £21.22; 30x54mg £36.80
- Indicated as part of a comprehensive treatment programme for ADHD in children aged 6 years of age and over when remedial measures alone prove insufficient.
 - A cost effective option. Agreed to add to formulary but wait and see whether there is any uptake
- Approved**
Add to formulary; **Amber TLS** **Action: Steve Moore**
- 7.11** Vencarm XL prolonged release capsules- Venlafaxine (Apsire Pharma Ltd); 28x37.5mg £3.30, 28x75mg £2.59, 28x150mg £3.89, 28x225mg £9.90
- Cost effective brand
- Approved**
Add to formulary; **Green TLS** **Action: Steve Moore**
- 8** **D&TC DECISIONS and other reports**
- 8.1** **Somerset Partnership D&TC- Last meeting 13/06/17 – Minutes received**
- Sondate XL will be prescribed for out-patients in line with the Somerset CCG formulary but in-patients may receive a different brand.
 - Olanzapine Depot is not recommended but they can administer on the ward with advanced warning if necessary.
 - A supply issue with Quetiapine immediate release was noted.
- 8.2** **YDH D&TC – Next meeting 09/08/17**
- No new minutes
- 8.3** **TST D&TC – Next meeting 28/07/17**
- No new minutes

8.4 Taunton & Somerset Antimicrobial Prescribing Group (TSAPG) – Last meeting 10/05/17 – minutes received

- Noted that there is a global shortage of Tazocin with stocks currently rationed and a price increase. It is likely to become unavailable. This will have an effect on co-amoxiclav and cephalosporin prescribing.

8.5 RUH Bath DTC – Last meetings 13/04/17 & 8/06/17– April Minutes received

- Spiriva to Braltus switch planned

8.6 BNSSG D&TC- Last meeting 17/05/17 – Minutes not received

No new minutes

8.7 BNSSG JFG- Last meeting 16/05/17 – Minutes received

- Methenamine added to formulary for the defined cohort (patients currently on nitrofurantoin whose renal function is less than 45ml/min would be the defined cohort)
- Degaralix TLS change. Proposal to change TLS status from red to amber. Feedback has been received from GPs who agreed it is suitable for change to amber. Awaiting SCP from Dr Ed Rowe at NBT. – **RED in Somerset**
- Symbicort MDI. It was agreed to include on the joint formulary as TLS green.
- Ivermectin cream, added to formulary for patients with moderate to severe erythematotelanectatic, popular, pustular rosacea as it allows GPs another option before a secondary care referral.
- In the process of launching a paediatric formulary website and organising a Paediatric Joint Formulary Group (PJG) meeting.
- Qtern (dapagliflozin and saxagliptin tabs) added to the formulary. – **Not recommended (Black) in Somerset.**

8.8 LPC report

ML not present

Part 2 – Items for information or noting

9 NICE Guidance Summary of published guidance -**Noted**

NICE Technology Appraisals

9.1 [TA444] Afatinib for treating advanced squamous non-small-cell lung cancer after platinum-based chemotherapy (terminated appraisal)

Not Recommended; Black TLS - update TLS

Action: Steve Moore

9.2 [TA445] Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs

Positive appraisal; add to TLS as per NICE Guidance with note that this is CCG commissioned. **Red TLS** - update TLS

Action: Steve Moore

SG noted that there is no formal pathway for treatment of psoriatic arthritis across Somerset, but the CCG may look to develop one.

9.3 [TA446] Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma

Positive appraisal; add to TLS as per NICE Guidance with note that this is **NHSE**

commissioned. **Red TLS** - update TLS **Action: Steve Moore**

9.4 [TA447] Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer

Positive appraisal; add to TLS as per NICE Guidance with note that this is **NHSE commissioned. Red TLS** - update TLS **Action: Steve Moore**

9.5 [TA448] Etelcalcetide for treating secondary hyperparathyroidism

Positive appraisal; add to TLS as per NICE Guidance with note that this is **NHSE commissioned. Red TLS** - update TLS **Action: Steve Moore**

9.6 [TA449] Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease

Positive appraisal; add to TLS as per NICE Guidance with note that this is **NHSE commissioned. Red TLS** - update TLS **Action: Steve Moore**

9.7 [TA450] Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia

Positive appraisal; add to TLS as per NICE Guidance with note that this is **NHSE commissioned. Red TLS** - update TLS **Action: Steve Moore**

9.8 [TA451] Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia

Positive appraisal; add to TLS as per NICE Guidance with note that this is **NHSE commissioned. Red TLS** - update TLS **Action: Steve Moore**

9.9 [TA452] Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal)

Not Recommended; Black TLS - update TLS **Action: Steve Moore**

9.10 [TA453] Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal)

Not Recommended; Black TLS - update TLS **Action: Steve Moore**

9.11 [TA454] Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (terminated appraisal)

Not Recommended; Black TLS - update TLS **Action: Steve Moore**

9.12 [TA455] Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people

Positive appraisal; add to TLS as per NICE Guidance. **Red TLS** - update TLS **Action: Steve Moore**

Funding position – CCG or NHSE needs to be clarified. **Action: SG**

9.13 [TA456] Ustekinumab for moderately to severely active Crohn's disease after previous treatment

Positive appraisal; add to TLS as per NICE Guidance with note that this is CCG commissioned. **Red TLS** - update TLS **Action: Steve Moore**

- 10 NICE Clinical Guidance**
- 10.1 [NG65] Spondyloarthritis in over 16s: diagnosis and management**
June 2017, updated recommendation 2.1.7 to clarify the advice on what imaging should be done. **- Noted**
- 10.2 [NG69] Eating disorders: recognition and treatment**
- Noted
- 10.3 [CG174] Intravenous fluid therapy in adults in hospital**
May 2017, some research recommendations that had become outdated since original publication were stood down and deleted. **- Noted**
- 10.4 [CG176] Head injury: assessment and early management**
June 2017, updated recommendations 1.2.8 and 1.4.12 with cross-references to related NICE guidelines, and an outdated research recommendation was deleted. **- Noted**
- 10.5 [PH56] Vitamin D: increasing supplement use in at-risk groups**
May 2017, updated introduction, recommendations 1 and 6, the context section and the glossary after publication of The SACN vitamin D and health report 2016. Amended at-risk age ranges, updated links to the new report and updated reference nutrient intake details. **- Noted**
- 10.6 [NG70] Air pollution: outdoor air quality and health**
No prescribing related issues **- Noted**
- 10.7 FAD – Roflumilast for treating chronic obstructive pulmonary disease**
Positive FAD- agreed to commission as soon as TAG published, provided there are no changes to the FAD. **Amber** TLS status.
Check TAG once published: **Action CH**
- 10.8 FAD – Collagenase clostridium histolyticum for treating Dupuytren’s contracture**
Positive FAD- agreed to commission as soon as final TAG published, provided there are no changes to the FAD.
- Check TAG once published: **Action CH**
 - Revisit Dupuytren’s surgery commissioning policy **Action SG**
 - Communicate to Oasis Team **Action L**
- 10.9 FAD – Baricitinib for moderate to severe rheumatoid arthritis**
Oral therapy. Positive FAD- agreed to commission as soon as TAG published, provided there are no changes to the FAD.
SG to start discussions with Trust specialists. **Action SG**
- 10.10 [CG99] Constipation in children and young people: diagnosis and management**
Guidance noted

11 NHS ENGLAND SPECIALIST COMMISSIONING

SG noted that a CCG policy on continuous blood glucose monitoring has been approved to reinforce the case that this is not routinely commissioned. However, specialists are welcome to raise a business case via the new 'risk sharing' routes.

LH noted that NHSE should provide funding for HIV Post Exposure Prophylaxis medications.

12 PBR excluded drug monitoring

12.1 T & S Trust Data- Month

SG to raise issues with data provided with format of the commissioning team and the system wide Finance and Information Group. **Action SG**

12.2 YDH Trust data- Month

- Showing a projected underspend of approx. £15k
- Large overperformance on aflibercept- this is expected to improve slightly
- There will be pressure from above if Trusts overspend.

SG noted that he attends meetings looking at high cost drug expenditure in other Trusts

13 HORIZON SCANNING

13.1 NICE forward planner - Noted

14 DRUG SAFETY

14.1 MHRA Drug Safety Update May 17 – eNewsletter - noted

14.2 MHRA Drug Safety Update June 17 – eNewsletter – noted

14.3 PSA alert: Risk of death and severe harm from ingestion of superabsorbent polymer gel granules- noted

15 BNF Changes

June eNewsletter – **Noted**

16 ANY OTHER BUSINESS

JS noted the STP plan around 'stop smoking' – ambition is that all smokers get nicotine replacement therapy as inpatients. Unsure of mechanism but Trusts are liaising with public health.

DATE OF NEXT MEETING

20th September 2017 at Wynford House (Meeting Room 1), Lufton Way, Yeovil, Somerset BA22 8HR between 2.30pm and 5pm

SOMERSET PRESCRIBING FORUM
SCHEDULE OF ACTIONS ARISING FROM THE MEETING HELD ON 19th July 2017

NO.	SUBJECT	OUTSTANDING RESPONSIBILITY	ACTION LEAD	Status
1	Declarations of interest (1)	Members were asked to notify the Prescribing Forum secretary of any standing declarations of interest, which could be held on record.	All (on going)	Ongoing
2	LMWH Bridging Guidance- YDH	Add to September agenda.	Catherine Henley 20 th Sept 17	Complete
3	Traffic light status of SSRIs in under 18 year olds guidance	Amber Traffic Light Status (TLS) agreed and agreed form of words will be added to the formulary regarding guidance in this group.	Catherine Henley 20 th Sept 17	Complete
4	Review of SPF Terms of Reference	Amend and finalise as per minutes.	Catherine Henley 20 th Sept 17	Complete
5	Antipsychotics in learning difficulties – SomPar data	Bring report to Sept meeting, if ready.	Liz Harewood 20 th Sept 17	On agenda
6	IBS Pathway	Members should feedback formal comments to JS	All 20 th Sept 17	
7	Lithium Shared Care Protocol	Amend as per minutes	Catherine Henley 20 th Sept 17	Complete
8	ALAI & PP3M with inclusion in shared care arrangement	Clarify LMC position on including aripiprazole and include in Shared Care protocol for Depo antipsychotics as appropriate	Catherine Henley	Complete
9	NICE [TA455] Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people	Clarify CCG or NHSE funding	Shaun Green 20 th Sept 17	Complete
10	FAD – Roflumilast for treating COPD	Check TAG once published and pass to Steve Moore to add to TLS, if no change (Amber status)	Catherine Henley 20 th Sept 17	Complete
11	FAD – Collagenase clostridium histolyticum for treating Dupuytren's contracture	<ul style="list-style-type: none"> • Check TAG once published and pass to Steve Moore to add to TLS, if no change (Red status) • Revisit commissioning policy • Communicate to Oasis Team 	Catherine Henley Shaun Green Liz Harewood 20 th Sept 17	

NO.	SUBJECT	OUTSTANDING RESPONSIBILITY	ACTION LEAD	Status
	Traffic Light System changes Cont.	<ul style="list-style-type: none"> • [TA446] NICE guidance: TLS status RED 'funded by NHSE Specialist Commissioning' • [TA447] NICE guidance: TLS status RED 'funded by NHSE Specialist Commissioning'. • [TA448] NICE guidance: TLS status RED drug. 'funded by NHSE Specialist Commissioning'. • [TA449] NICE guidance: TLS status RED 'funded by NHSE Specialist Commissioning'. • [TA450] NICE guidance: TLS status RED 'funded by NHSE Specialist Commissioning'. • [TA451] NICE guidance: TLS status RED 'funded by NHSE Specialist Commissioning'. • [TA452] NICE guidance: TLS status BLACK 'not recommended'. • [TA453] NICE guidance: TLS status BLACK 'not recommended'. • [TA454] NICE guidance: TLS status BLACK 'not recommended'. • [TA455] NICE guidance: TLS status RED • [TA456] NICE guidance: TLS status RED 'funded by CCG'. 		